Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline phils inc - cimetidine - tablet - 200mg

Canada - English - Health Canada

glaxosmithkline inc - cimetidine - tablet - 300mg - cimetidine 300mg - histamine h2-antagonists

Canada - English - Health Canada

glaxosmithkline inc - cimetidine - tablet - 600mg - cimetidine 600mg - histamine h2-antagonists

Canada - English - Health Canada

glaxosmithkline inc - cimetidine - tablet - 400mg - cimetidine 400mg - histamine h2-antagonists

Canada - English - Health Canada

smithkline beecham pharma division of smithkline beecham inc - cimetidine (cimetidine hydrochloride) - liquid - 150mg - cimetidine (cimetidine hydrochloride) 150mg - histamine h2-antagonists

Canada - English - Health Canada

smithkline beecham pharma division of smithkline beecham inc - cimetidine hydrochloride - liquid - 6mg - cimetidine hydrochloride 6mg - histamine h2-antagonists

United States - English - NLM (National Library of Medicine)

stat rx usa llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c), naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - morphine sulfate 20 mg - embeda is an extended-release oral formulation of morphine sulfate and naltrexone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. embeda is not intended for use as a prn analgesic. embeda is not indicated for acute/postoperative pain or if the pain is mild or not expected to persist for an extended period of time. embeda is only indicated for postoperative use if the patient is already receiving chronic opioid therapy prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate embeda is contraindicated in patients with a known hypersensitivity to morphine, morphine salts, naltrexone, or in any situation where opioids are contraindicated. embeda is contraindicated in patients with significant respiratory depression in u

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.22 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; microcrystalline cellulose; mannitol; basic butylated methacrylate copolymer; titanium dioxide; purified talc; polyvinyl alcohol; sodium lauryl sulfate; glyceryl monostearate - treatment of major depression and for the prevention of relapse of depressive symptoms; treatment of obsessive compulsive disorder and for the prevention of relapse of ocd; treatment of panic disorder and for the prevention of relapse of panic disorder; treatment of social anxiety disorder/ social phobia; treatment of generalised anxiety disorder; and treatment of post-traumatic stress disorder

United States - English - NLM (National Library of Medicine)

atlantic biologicals corps - diazepam (unii: q3jtx2q7tu) (diazepam - unii:q3jtx2q7tu) - diazepam 5 mg in 5 ml - diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. in acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome. oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. the effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - paroxetine hydrochloride hemihydrate, quantity: 22.2 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; sodium starch glycollate type a; calcium hydrogen phosphate dihydrate; calcium hydrogen phosphate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - for the treatment of:,? major depression and for the prevention of relapse of depressive symptoms;,? obsessive compulsive disorder and for the prevention of relapse of ocd;,? panic disorder and for the prevention of relapse of panic disorder;,? social anxiety disorder/social phobia; and,? generalised anxiety disorder;,? posttraumatic stress disorder.